Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bio Key International (BKYI) EBITDA Margin (2016 - 2025)

Bio Key International (BKYI) has disclosed EBITDA Margin for 16 consecutive years, with 67.03% as the latest value for Q3 2025.

  • Quarterly EBITDA Margin fell 3677.0% to 67.03% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 67.87% through Sep 2025, up 205.0% year-over-year, with the annual reading at 61.68% for FY2024, 4479.0% up from the prior year.
  • EBITDA Margin hit 67.03% in Q3 2025 for Bio Key International, down from 65.33% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 26.25% in Q1 2024 to a low of 386.84% in Q4 2022.
  • Historically, EBITDA Margin has averaged 108.75% across 5 years, with a median of 96.42% in 2024.
  • Biggest five-year swings in EBITDA Margin: soared 34732bps in 2021 and later crashed -17299bps in 2022.
  • Year by year, EBITDA Margin stood at 213.85% in 2021, then tumbled by -81bps to 386.84% in 2022, then soared by 68bps to 122.45% in 2023, then grew by 21bps to 96.42% in 2024, then soared by 30bps to 67.03% in 2025.
  • Business Quant data shows EBITDA Margin for BKYI at 67.03% in Q3 2025, 65.33% in Q2 2025, and 45.41% in Q1 2025.